153 related articles for article (PubMed ID: 36874988)
1. A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma.
Fukiishi Y; Fukuhara H; Kurano Y; Shugimoto H; Yamashita E; Karasima T; Inoue K
IJU Case Rep; 2023 Mar; 6(2):128-132. PubMed ID: 36874988
[TBL] [Abstract][Full Text] [Related]
2. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of metastatic bladder cancer by gemcitabine-cisplatin re-challenge after pembrolizumab.
Arai T; Takeuchi N; Sazuka T; Sato H; Imamura Y; Sakamoto S; Komiya A; Ichikawa T
IJU Case Rep; 2021 Nov; 4(6):360-362. PubMed ID: 34755056
[TBL] [Abstract][Full Text] [Related]
5. Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
Miyake M; Shimizu T; Nishimura N; Kiba K; Maesaka F; Oda Y; Tachibana A; Tomizawa M; Ohmori C; Matsumura Y; Ichikawa K; Mizobuchi S; Yoshikawa T; Hori S; Morizawa Y; Gotoh D; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Fujimoto K;
Clin Genitourin Cancer; 2022 Apr; 20(2):196.e1-196.e9. PubMed ID: 34916166
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Hale O; Patterson K; Lai Y; Meng Y; Li H; Godwin JL; Homet Moreno B; Mamtani R
Clin Genitourin Cancer; 2021 Feb; 19(1):e17-e30. PubMed ID: 32826180
[TBL] [Abstract][Full Text] [Related]
7. Severe gastritis due to pembrolizumab treatment in a lung cancer patient.
Hayama N; Ihara H; Honma Y; Itoigawa Y; Kaira K; Fujii M
Respirol Case Rep; 2020 Oct; 8(7):e00636. PubMed ID: 35600796
[TBL] [Abstract][Full Text] [Related]
8. Severe Gastritis after Administration of Nivolumab and Ipilimumab.
Nishimura Y; Yasuda M; Ocho K; Iwamuro M; Yamasaki O; Tanaka T; Otsuka F
Case Rep Oncol; 2018; 11(2):549-556. PubMed ID: 30186138
[TBL] [Abstract][Full Text] [Related]
9. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
10. [ONE COURSE OF PEMBROLIZUMAB AFTER RADIATION THERAPY WAS VERY EFFECTIVE AGAINST METASTATIC BLADDER CANCER AND CR WAS CONFIRMED: A CASE REPORT].
Sakamoto T; Fujimoto N; Nakashima M
Nihon Hinyokika Gakkai Zasshi; 2021; 112(4):220-223. PubMed ID: 36261353
[TBL] [Abstract][Full Text] [Related]
11. Temporal observation of endoscopic and histological findings of gastritis after administration of an immune checkpoint inhibitor: a case report.
Saito K; Ozono D; Nagumo H; Yoshimura M; Masuzawa Y
Clin J Gastroenterol; 2022 Apr; 15(2):368-373. PubMed ID: 34985687
[TBL] [Abstract][Full Text] [Related]
12. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.
Hayakawa N; Kikuchi E; Suzuki S; Oya M
Int Cancer Conf J; 2020 Jul; 9(3):123-126. PubMed ID: 32582515
[TBL] [Abstract][Full Text] [Related]
13. Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma.
Fukuta K; Izaki H; Shiozaki K; Nakanishi R; Inai T; Kataoka H; Kudo E; Kanda K
IJU Case Rep; 2021 Sep; 4(5):310-313. PubMed ID: 34497992
[TBL] [Abstract][Full Text] [Related]
14. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Thomas S; Bae C; Joy-Ann T; Traverse W
J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab.
Hatayama T; Hayashi T; Matsuzaki S; Masumoto H; Yanai H; Abdi H; Teishima J; Hasegawa Y
IJU Case Rep; 2020 Nov; 3(6):252-256. PubMed ID: 33163917
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Rose TL; Harrison MR; Deal AM; Ramalingam S; Whang YE; Brower B; Dunn M; Osterman CK; Heiling HM; Bjurlin MA; Smith AB; Nielsen ME; Tan HJ; Wallen E; Woods ME; George D; Zhang T; Drier A; Kim WY; Milowsky MI
J Clin Oncol; 2021 Oct; 39(28):3140-3148. PubMed ID: 34428076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
